Fenofibric Acid: a New Fibrate Approved for Use in Combination with Statin for the Treatment of Mixed Dyslipidemia

Overview

Journal Vasc Health Risk Manag

Publisher Dove Medical Press

Specialty Cardiology & Vascular Diseases

Date 2010 Jun 10

PMID 20531954

Citations 13

Authors

Peter Alagona Jr

Affiliations

Soon will be listed here.

Abstract

The last two to three decades have seen an explosive growth in interest and information regarding cardiovascular disease (CVD) risk assessment and treatment. Evidence for the role of low-density lipoprotein (LDL) in risk has led to a series of clinical guidelines/recommendations on the importance of LDL lowering with statin treatment. There is also substantial evidence on a number of lipoproteins in the initiation and progression of atherosclerosis and CV events. Health care professionals have not embraced easily novel approaches to identifying those at increased risk and more aggressive treatment. This is especially true for non-LDL factors. The use of non-statin drugs such as fibrates has been modest and many health care professionals avoid consideration of combination therapy due to an inordinate fear of toxicity. This review will attempt to provide appropriate background information on lipids/lipoproteins, including non-high density lipoprotein and risk, as well as data available on fibrates and combination pharmacologic therapy. We will review a new agent, TriLipix((R)) (fenofibric acid), and its potential role in treatment.

Citing Articles

A Mendelian randomization study for drug repurposing reveals bezafibrate and fenofibric acid as potential osteoporosis treatments.

Li X, Pang W, Zhang Y, Liu D, Yi Q, Wang N Front Pharmacol. 2023; 14:1211302.

PMID: 37547327 PMC: 10397407. DOI: 10.3389/fphar.2023.1211302.

Development of Pharmaceutical Nanomedicines: From the Bench to the Market.

Halwani A Pharmaceutics. 2022; 14(1).

PMID: 35057002 PMC: 8777701. DOI: 10.3390/pharmaceutics14010106.

Targeting Peroxisome Proliferator-Activated Receptor-α (PPAR- α) to reduce paclitaxel-induced peripheral neuropathy.

Caillaud M, Patel N, White A, Wood M, Contreras K, Toma W Brain Behav Immun. 2021; 93:172-185.

PMID: 33434562 PMC: 8226373. DOI: 10.1016/j.bbi.2021.01.004.

A Fenofibrate Diet Prevents Paclitaxel-Induced Peripheral Neuropathy in Mice.

Caillaud M, Patel N, Toma W, White A, Thompson D, Mann J Cancers (Basel). 2021; 13(1).

PMID: 33383736 PMC: 7795224. DOI: 10.3390/cancers13010069.

Comparative and Evaluation of Fenofibric Acid as an Antihyperlipidemic Drug.

Windriyati Y, Sumirtapura Y, Pamudji J Turk J Pharm Sci. 2020; 17(2):203-210.

PMID: 32454781 PMC: 7227912. DOI: 10.4274/tjps.galenos.2019.27147.

References

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

Lahdenpera S, Kuusi T, Taskinen M . Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. Diabetes Care. 1993; 16(4):584-92. DOI: 10.2337/diacare.16.4.584. View

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-39. DOI: 10.1161/01.CIR.0000133317.49796.0E. View

Mohiuddin S, Pepine C, Kelly M, Buttler S, Setze C, Sleep D . Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2008; 157(1):195-203. DOI: 10.1016/j.ahj.2008.08.027. View

LaRosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart J . Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352(14):1425-35. DOI: 10.1056/NEJMoa050461. View

Hottelart C, El Esper N, Rose F, Achard J, Fournier A . Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002; 92(3):536-41. DOI: 10.1159/000064083. View

Berger J, Moller D . The mechanisms of action of PPARs. Annu Rev Med. 2002; 53:409-35. DOI: 10.1146/annurev.med.53.082901.104018. View

CASTELLI W, Garrison R, Wilson P, Abbott R, Kalousdian S, Kannel W . Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986; 256(20):2835-8. View

Haim M, Benderly M, Brunner D, Behar S, Graff E, Reicher-Reiss H . Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation. 1999; 100(5):475-82. DOI: 10.1161/01.cir.100.5.475. View

10.

Gordon D, Probstfield J, Garrison R, Neaton J, CASTELLI W, Knoke J . High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989; 79(1):8-15. DOI: 10.1161/01.cir.79.1.8. View

11.

Farnier M, Roth E, Gil-Extremera B, Mendez G, Macdonell G, Hamlin C . Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J. 2007; 153(2):335.e1-8. DOI: 10.1016/j.ahj.2006.10.031. View

12.

CASTELLI W . Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol. 1988; 4 Suppl A:5A-10A. View

13.

BRADFORD R, Goldberg A, Schonfeld G, Knopp R . Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia. Atherosclerosis. 1992; 92(1):31-40. DOI: 10.1016/0021-9150(92)90007-4. View

14.

Jones P, Bays H, Davidson M, Kelly M, Buttler S, Setze C . Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008; 28(10):625-34. DOI: 10.2165/00044011-200828100-00003. View

15.

Tonelli M, Collins D, Robins S, Bloomfield H, Curhan G . Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am J Kidney Dis. 2004; 44(5):832-9. View

16.

Gordon T, CASTELLI W, Hjortland M, Kannel W, DAWBER T . High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977; 62(5):707-14. DOI: 10.1016/0002-9343(77)90874-9. View

17.

Farnier M, Freeman M, Macdonell G, Perevozskaya I, Davies M, Mitchel Y . Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J. 2005; 26(9):897-905. DOI: 10.1093/eurheartj/ehi231. View

18.

Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z . Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther. 2004; 42(4):212-7. DOI: 10.5414/cpp42212. View

19.

Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis D, Elisaf M . Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther. 2002; 7(4):219-26. DOI: 10.1177/107424840200700404. View

20.

Pedersen T, Faergeman O, Kastelein J, Olsson A, Tikkanen M, Holme I . High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005; 294(19):2437-45. DOI: 10.1001/jama.294.19.2437. View